Giving intravenous iron to patients with symptomatic heart failure is safe and cost effective.
Br J Hosp Med (Lond)
; 82(5): 1-5, 2021 May 02.
Article
em En
| MEDLINE
| ID: mdl-34076520
ABSTRACT
AIMS/BACKGROUND:
Heart failure affects approximately 1 million people in the UK, adversely affecting quality of life, functional capacity and cognitive health. Iron deficiency complicates heart failure in approximately 50% of patients. Giving intravenous ferric carboxymaltose has been shown to improve quality of life in patients with heart failure (New York Heart Association class and Kansas City Cardiomyopathy Questionnaire).METHODS:
A quality improvement project was designed to assess the feasibility, safety and cost implications of establishing an intravenous iron service in the authors' centre.RESULTS:
Between July and December 2019 61 patients who were screened met the inclusion criteria and were administered intravenous ferric carboxymaltose. There were statistically significant improvements in ferritin levels (83.3 ug/litre to 433 ug/litre; P<0.0001), transferrin saturation (18% to 30% P<0.0001) and haemoglobin levels (126 g/litre to 135 g/litre; P<0.01). No demonstrable changes in New York Heart Association class or quality of life scores were noted. The overall financial impact for the trust was income generation of £14 665, a net income of £240 per patient.CONCLUSIONS:
Intravenous iron replacement with ferric carboxymaltose is safe and cost effective, and should be considered in eligible iron-deficient patients with symptomatic heart failure. Integration with another day case intravenous service represented the most logistically simple and economically viable method of service delivery.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Anemia Ferropriva
/
Insuficiência Cardíaca
Tipo de estudo:
Diagnostic_studies
/
Health_economic_evaluation
Limite:
Humans
Idioma:
En
Revista:
Br J Hosp Med (Lond)
Assunto da revista:
HOSPITAIS
/
MEDICINA
Ano de publicação:
2021
Tipo de documento:
Article
País de afiliação:
Reino Unido